clinical trial · NCT04594798
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
DLBCLLymphoma, B-CellPolatuzumab vedotinRituximabCyclophosphamideDoxorubicinPrednisone
brief summary
The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.
started
Sep 20, 2021
primary completion
Jul 31, 2026
completion
Jul 31, 2026
last updated
Dec 17, 2025
detailed description
In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.
official title
Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol